I am a
Home I AM A Search Login

Papers of the Week

Papers: 25 Dec 2021 - 31 Dec 2021

Human Studies, Pharmacology/Drug Development

2021 Dec 27




A mechanism-based proof of concept study on the effects of duloxetine in patients with painful knee osteoarthritis.


Ammitzbøll N, Arendt-Nielsen L, Bertoli D, Brock C, Olesen A E, Kappel A, Drewes A M, Petersen K K
Trials. 2021 Dec 27; 22(1):958.
PMID: 34961547.


The global burden of osteoarthritis (OA) is steadily increasing due to demographic and lifestyle changes. The nervous system can undergo peripheral and central neuroplastic changes (sensitization) in patients with OA impacting the options to manage the pain adequately. As a result of sensitization, patients with OA show lower pressure pain thresholds (PPTs), facilitated temporal summation of pain (TSP), and impaired conditioned pain modulation (CPM). As traditional analgesics (acetaminophen and non-steroidal anti-inflammatory drugs) are not recommended for long-term use in OA, more fundamental knowledge related to other possible management regimes are needed. Duloxetine is a serotonin-noradrenalin reuptake inhibitor, and analgesic effects are documented in patients with OA although the underlying fundamental mechanisms remain unclear. The descending pain inhibitory control system is believed to be dependent on serotonin and noradrenalin. We hypothesized that the analgesic effect of duloxetine could act through these pathways and consequently indirectly reduce pain and sensitization. The aim of this mechanistic study is to investigate if PPTs, TSP, CPM, and clinical pain parameters are modulated by duloxetine.